Short Term Fellowship


EFIS and Immunology Letters (IL) award short-term fellowships for up to 3 months of support for purposes of transnational scientific collaboration or advanced training in techniques or methodologies. The EFIS-IL Short-term Fellowship allowance is € 1.750/month and is awarded directly to the fellowship holder. In addition, EFIS will reimburse travel costs up to € 500. Eligibility criteria follow below.


Congratulations to the most recent recipients of EFIS-IL Short-term Fellowships (approved October 21st, 2017)

  • Farhan Basit (NVvI), from Amsterdam to Madrid, to study the “Functional analysis of metabolic adaptations in BDCA3+ (CD141+) dendritic cells derived from healthy donors and cancer patients upon TLR-stimulation” c/o the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC);
  • Neda Đjedović (ISoS), from Belgrade to Badalona, to conduct research on “Ethyl pyruvate impact on humane dendritic cells” c/o the Germans Trias I Pujol University Hospital and Research Institute;
  • Marta Bermejo Jambrina (ÖGAI), from Innsbruck to Amsterdam, for studies on “Mechanistic insights into complement-induced mechanisms of HIV-1 in Langerhans Cells (LCs)” c/o the Academisch Medisch Centrum;
  • Ana Martín Leal (SEI), from Madrid to Freiburg, to train in “Blue Native PAGE to study CCR5-mediated TCR nanoclustering formation and the importance of ceramides in this process” c/o the Institute for Biology III of the Albert-Ludwigs-University;
  • Victor Muñoz Abad (SEI), from Madrid to Paris, to conduct research on the “Role of TAPL in TAP-independent presentation” c/o the Institut Necker Enfants Malades;
  • Sara Signa (SIICA), from Genoa to Newcastle upon Tyne, to study the “Outcome of stem cell transplants for the complement autoimmune and autoinflammatory patients” c/o the Bone Marrow Transplant Unit of the Great North Children’s Hospital;
  • Donatella Galgano (SIICA), from Stockholm to Homburg (DE), for a project on “Dissecting the function of two distinct Munc13-4 isoforms by super resolution microscopy” c/o the Department of Physiology of Saarland University;
  • Anna Roppelt (RSI), from Moscow to London, to conduct research on “Gene editing of XIAP using CRISPR/Cas system as a potential therapeutic approach for patients with X-linked lymphoproliferative syndrome type 2” c/o the UCL Great Ormond Street Institute of Child Health.

Distribution of EFIS-IL Fellowships by Society and by Destination 2010 - 2017



Eligibility Criteria:

  • Applicants must be a member of an EFIS-affiliated society (exceptions to this may apply only for applicants from European countries without a national society);
  • Applicants must be 35 years of age or younger and must hold at least a Master's degree (an extension of this age limit of up to 18 months may be granted for maternity/paternity leave, civil or military service, etc.);
  • The proposed stay must be conducted in a European institution;
  • Fellowships are not awarded in order to attend courses, symposia, meetings or congresses;
  • Fellowships are not renewable and can be held only once;
  • Fellowships cannot be held simultaneously with awards or funding made available by other sources or organizations, nor can they be used to prolong visits begun under other auspices, or as a means to bridge between research visits funded by other organizations.

To apply for an EFIS-IL short-term fellowship, please provide all required information in the online application form below.


Documents to submit:

  • Short curriculum vitae (.doc or .pdf)
  • List of publications (.doc or .pdf)
  • Project proposal (max 2 pages, .doc or .pdf). The proposal should include summary and aim, background and operational objectives and working plan
  • Letter of recommendation (not from the receiving institute) (.doc or .pdf)
  • Acceptance letter from the head/supervisor of receiving Institute (.doc or .pdf)
  • Proof of membership in an EFIS-affiliated society (.doc or .pdf)


The EFIS Board evaluates applications at its periodic board meetings, held every 3-4 months.

January 26th, 2018